Back to Search
Start Over
The development of small-molecule inhibitors targeting CD47
- Source :
- Drug discovery today. 26(2)
- Publication Year :
- 2020
-
Abstract
- Immunotherapy has become an indispensable part of cancer treatment. A pivotal phagocytosis checkpoint, named cluster of differentiation 47 (CD47), which functions as 'don't eat me' signal to protect cells from phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) on macrophages, has recently attracted much attention. Numerous antibodies targeting the CD47/SIRPα axis have shown encouraging efficacy in clinical trials. Meanwhile, studies on small-molecule inhibitors that interfere with CD47/SIRPα interaction or regulate CD47 expression are also in full swing. In this review, we summarize the small-molecule inhibitors interrupting the binding of CD47/SIRPα and regulating CD47 at the transcriptional, translational, and post-translational modification (PTM) levels. We provide perspectives and strategies for targeting the CD47/SIRPα phagocytosis checkpoint.
- Subjects :
- 0301 basic medicine
medicine.medical_treatment
Phagocytosis
Antineoplastic Agents
CD47 Antigen
Biology
Antibodies
03 medical and health sciences
0302 clinical medicine
Drug Development
Neoplasms
Drug Discovery
Signal-regulatory protein alpha
medicine
Animals
Humans
Molecular Targeted Therapy
Pharmacology
Cluster of differentiation
CD47
Macrophages
Immunotherapy
Small molecule
Cell biology
Cancer treatment
030104 developmental biology
030220 oncology & carcinogenesis
biology.protein
Antibody
Subjects
Details
- ISSN :
- 18785832
- Volume :
- 26
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Drug discovery today
- Accession number :
- edsair.doi.dedup.....eccdb5d326367ae3b631ab036fcdff21